Verona Pharma PLCNASDAQ:VRNA
- LAST PRICE15.6900
- TODAY'S CHANGE (%)-0.0600 (-0.3810%)
- Bid / Lots15.6600/ 1
- Ask / Lots16.4900/ 20
- Open / Previous Close15.8600 / 15.7500
- Day Range
- 52 Week Range
- Volume507,486
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VRNA |
|---|---|---|
| 09:32 ET | 66437 | 15.64 |
| 09:34 ET | 2900 | 15.7 |
| 09:36 ET | 1918 | 15.7 |
| 09:38 ET | 3779 | 15.65 |
| 09:39 ET | 892 | 15.61 |
| 09:43 ET | 2220 | 15.55 |
| 09:45 ET | 3114 | 15.5601 |
| 09:48 ET | 118 | 15.56 |
| 09:50 ET | 800 | 15.58 |
| 09:52 ET | 1500 | 15.55 |
| 09:54 ET | 600 | 15.69 |
| 09:56 ET | 300 | 15.735 |
| 09:57 ET | 400 | 15.7 |
| 09:59 ET | 350 | 15.66 |
| 10:01 ET | 2000 | 15.59 |
| 10:06 ET | 748 | 15.55 |
| 10:08 ET | 711 | 15.54 |
| 10:10 ET | 200 | 15.53 |
| 10:12 ET | 2500 | 15.58 |
| 10:14 ET | 3264 | 15.56 |
| 10:15 ET | 300 | 15.59 |
| 10:17 ET | 800 | 15.54 |
| 10:19 ET | 1540 | 15.47 |
| 10:21 ET | 1400 | 15.515 |
| 10:24 ET | 400 | 15.5066 |
| 10:26 ET | 600 | 15.495 |
| 10:28 ET | 200 | 15.495 |
| 10:30 ET | 700 | 15.54 |
| 10:32 ET | 2274 | 15.6 |
| 10:33 ET | 300 | 15.59 |
| 10:35 ET | 100 | 15.57 |
| 10:37 ET | 260 | 15.55 |
| 10:39 ET | 100 | 15.57 |
| 10:44 ET | 300 | 15.54 |
| 10:46 ET | 400 | 15.5 |
| 10:48 ET | 1144 | 15.53 |
| 10:50 ET | 100 | 15.51 |
| 10:51 ET | 600 | 15.53 |
| 10:55 ET | 290 | 15.56 |
| 10:57 ET | 300 | 15.58 |
| 11:00 ET | 300 | 15.565 |
| 11:02 ET | 144 | 15.58 |
| 11:04 ET | 617 | 15.62 |
| 11:06 ET | 300 | 15.61 |
| 11:08 ET | 100 | 15.61 |
| 11:09 ET | 500 | 15.555 |
| 11:11 ET | 200 | 15.5501 |
| 11:13 ET | 200 | 15.56 |
| 11:15 ET | 2948 | 15.59 |
| 11:18 ET | 575 | 15.605 |
| 11:20 ET | 200 | 15.6106 |
| 11:22 ET | 1505 | 15.58 |
| 11:24 ET | 200 | 15.59 |
| 11:27 ET | 100 | 15.59 |
| 11:29 ET | 1700 | 15.6 |
| 11:31 ET | 1000 | 15.64 |
| 11:33 ET | 815 | 15.68 |
| 11:36 ET | 75690 | 15.685 |
| 11:40 ET | 100 | 15.69 |
| 11:42 ET | 543 | 15.72 |
| 11:44 ET | 3047 | 15.79 |
| 11:45 ET | 421 | 15.8099 |
| 11:47 ET | 300 | 15.71 |
| 11:51 ET | 5385 | 15.75 |
| 11:54 ET | 400 | 15.74 |
| 11:56 ET | 2100 | 15.74 |
| 11:58 ET | 600 | 15.69 |
| 12:00 ET | 100 | 15.685 |
| 12:05 ET | 731 | 15.67 |
| 12:07 ET | 100 | 15.65 |
| 12:12 ET | 100 | 15.67 |
| 12:16 ET | 700 | 15.67 |
| 12:20 ET | 1895 | 15.6391 |
| 12:23 ET | 890 | 15.635 |
| 12:25 ET | 10238 | 15.635 |
| 12:27 ET | 100 | 15.635 |
| 12:30 ET | 790 | 15.63 |
| 12:32 ET | 300 | 15.62 |
| 12:36 ET | 2076 | 15.6213 |
| 12:38 ET | 343 | 15.67 |
| 12:39 ET | 200 | 15.7 |
| 12:43 ET | 200 | 15.67 |
| 12:45 ET | 1170 | 15.68 |
| 12:48 ET | 100 | 15.68 |
| 12:50 ET | 100 | 15.68 |
| 12:52 ET | 400 | 15.695 |
| 12:54 ET | 2733 | 15.68 |
| 12:56 ET | 1040 | 15.69 |
| 12:57 ET | 5100 | 15.7 |
| 01:01 ET | 400 | 15.675 |
| 01:03 ET | 500 | 15.67 |
| 01:08 ET | 700 | 15.65 |
| 01:10 ET | 100 | 15.655 |
| 01:12 ET | 200 | 15.655 |
| 01:15 ET | 100 | 15.66 |
| 01:17 ET | 1300 | 15.66 |
| 01:19 ET | 500 | 15.65 |
| 01:21 ET | 200 | 15.65 |
| 01:24 ET | 576 | 15.66 |
| 01:26 ET | 700 | 15.67 |
| 01:28 ET | 2694 | 15.685 |
| 01:30 ET | 100 | 15.68 |
| 01:32 ET | 149 | 15.6701 |
| 01:35 ET | 3400 | 15.69 |
| 01:37 ET | 100 | 15.69 |
| 01:39 ET | 600 | 15.69 |
| 01:42 ET | 400 | 15.69 |
| 01:44 ET | 900 | 15.67 |
| 01:48 ET | 100 | 15.655 |
| 01:50 ET | 400 | 15.64 |
| 01:55 ET | 500 | 15.67 |
| 02:00 ET | 200 | 15.69 |
| 02:02 ET | 539 | 15.69 |
| 02:06 ET | 300 | 15.715 |
| 02:09 ET | 300 | 15.73 |
| 02:11 ET | 10400 | 15.76 |
| 02:13 ET | 500 | 15.76 |
| 02:22 ET | 800 | 15.755 |
| 02:26 ET | 400 | 15.755 |
| 02:27 ET | 200 | 15.74 |
| 02:31 ET | 1327 | 15.74 |
| 02:33 ET | 1309 | 15.74 |
| 02:36 ET | 7654 | 15.73 |
| 02:40 ET | 900 | 15.71 |
| 02:42 ET | 1000 | 15.6899 |
| 02:44 ET | 240 | 15.7055 |
| 02:51 ET | 31915 | 15.7 |
| 02:54 ET | 324 | 15.715 |
| 02:56 ET | 900 | 15.69 |
| 02:58 ET | 1771 | 15.7 |
| 03:02 ET | 100 | 15.7 |
| 03:03 ET | 1338 | 15.65 |
| 03:05 ET | 1249 | 15.65 |
| 03:09 ET | 100 | 15.645 |
| 03:12 ET | 1300 | 15.64 |
| 03:14 ET | 100 | 15.63 |
| 03:16 ET | 1269 | 15.64 |
| 03:18 ET | 500 | 15.64 |
| 03:20 ET | 200 | 15.65 |
| 03:25 ET | 1600 | 15.63 |
| 03:30 ET | 8857 | 15.6 |
| 03:32 ET | 1680 | 15.625 |
| 03:34 ET | 100 | 15.625 |
| 03:36 ET | 200 | 15.625 |
| 03:38 ET | 2923 | 15.59 |
| 03:39 ET | 2136 | 15.59 |
| 03:41 ET | 1126 | 15.6 |
| 03:43 ET | 774 | 15.595 |
| 03:45 ET | 1900 | 15.6 |
| 03:48 ET | 2970 | 15.6 |
| 03:50 ET | 7268 | 15.615 |
| 03:52 ET | 4490 | 15.615 |
| 03:54 ET | 4333 | 15.65 |
| 03:56 ET | 10508 | 15.68 |
| 03:57 ET | 11373 | 15.695 |
| 03:59 ET | 20461 | 15.69 |
May 2, 2024
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024, from 2:00AM ET on Thursday May 02, 2024 by Dow Jones
2:00AM ET on Thursday May 02, 2024 by Dow Jones
Apr 25, 2024
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update, from 2:00AM ET on Thursday Apr 25, 2024 by Dow Jones
2:00AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 16, 2024
DJ Verona Pharma Is Maintained at Overweight by Piper Sandler, from 7:59AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:59AM ET on Tuesday Apr 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Verona Pharma PLC | 1.3B | -22.9x | --- |
Belite Bio Inc | 1.3B | -34.8x | --- |
Gyre Therapeutics Inc | 1.3B | -0.7x | --- |
Pharvaris NV | 1.2B | -8.3x | --- |
Scholar Rock Holding Corp | 1.2B | -7.7x | --- |
Spyre Therapeutics Inc | 1.3B | -0.5x | --- |
Company Information
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Contact Information
- Headquarters
- Riverside, 3 More London PlaceLONDON, United Kingdom SE1 2RE
- Phone
- 203-283-4200
- Fax
- 207-863-3314
Executives
- Non-Executive Independent Chairman of the Board
- David Ebsworth
- President, Chief Executive Officer, Executive Director
- David Zaccardelli
- Chief Financial Officer
- Mark Hahn
- General Counsel
- Claire Poll
- Chief Medical Officer
- Kathleen Rickard
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $-0.69 |
Book Value | $3.10 |
P/E Ratio | -22.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
